nitroglycerin has been researched along with Homocystinuria in 2 studies
Nitroglycerin: A volatile vasodilator which relieves ANGINA PECTORIS by stimulating GUANYLATE CYCLASE and lowering cytosolic calcium. It is also sometimes used for TOCOLYSIS and explosives.
nitroglycerol : A nitrate ester that is glycerol in which nitro group(s) replace the hydrogen(s) attached to one or more of the hydroxy groups.
nitroglycerin : A nitroglycerol that is glycerol in which the hydrogen atoms of all three hydroxy groups are replaced by nitro groups. It acts as a prodrug, releasing nitric oxide to open blood vessels and so alleviate heart pain.
Homocystinuria: Autosomal recessive inborn error of methionine metabolism usually caused by a deficiency of CYSTATHIONINE BETA-SYNTHASE and associated with elevations of homocysteine in plasma and urine. Clinical features include a tall slender habitus, SCOLIOSIS, arachnodactyly, MUSCLE WEAKNESS, genu varus, thin blond hair, malar flush, lens dislocations, an increased incidence of MENTAL RETARDATION, and a tendency to develop fibrosis of arteries, frequently complicated by CEREBROVASCULAR ACCIDENTS and MYOCARDIAL INFARCTION. (From Adams et al., Principles of Neurology, 6th ed, p979)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Homocystinuria is strongly associated with premature vascular disease in homozygotes, and even heterozygotes have been shown to be at increased risk from early atherosclerosis associated with hyperhomocystinemia." | 1.29 | Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents. ( Celermajer, DS; Deanfield, JE; Leonard, JV; Robinson, J; Ryalls, M; Sorensen, K; Thomas, O, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pullin, CH | 1 |
| Bonham, JR | 1 |
| McDowell, IF | 1 |
| Lee, PJ | 1 |
| Powers, HJ | 1 |
| Wilson, JF | 1 |
| Lewis, MJ | 1 |
| Moat, SJ | 1 |
| Celermajer, DS | 1 |
| Sorensen, K | 1 |
| Ryalls, M | 1 |
| Robinson, J | 1 |
| Thomas, O | 1 |
| Leonard, JV | 1 |
| Deanfield, JE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Impact of Spironolactone on Endothelial Function in Patients With Single Ventricle Heart[NCT00211081] | 12 participants (Actual) | Interventional | 2004-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Flow-mediated dilation of the brachial artery will be measured using high-resolution ultrasound. Arterial diameter will be measured above the small cavity in the elbow joint from ultrasound images at rest in response to an increase in blood flow to the area. (NCT00211081)
Timeframe: Baseline, Post-Intervention (4 Weeks)
| Intervention | Percentage of brachial artery diameter (Mean) |
|---|---|
| Spironolactone | 5.5 |
The normal reference range for C-reactive protein is as follows: CRP: 0-10mg/L (NCT00211081)
Timeframe: Baseline, Post-Intervention (4 Weeks)
| Intervention | mg/L (Median) | |
|---|---|---|
| Baseline | 4 Week Follow Up | |
| Spironolactone | 1.10 | 1.10 |
The normal result for IL1b is <3.9 pg/mL. (NCT00211081)
Timeframe: Baseline, Post-Intervention (4 Weeks)
| Intervention | pg/mL (Median) | |
|---|---|---|
| Baseline | 4 Week Follow Up | |
| Spironolactone | .38 | .23 |
The normal result for IL-10 for Interleukin 10 is < 18pg/ml. (NCT00211081)
Timeframe: Baseline, Post-Intervention (4 Weeks)
| Intervention | 18pg/ml (Median) | |
|---|---|---|
| Baseline | 4 Week Follow Up | |
| Spironolactone | .26 | .13 |
The normal result for IL-6 for Interleukin 6 is < 5pg/ml. (NCT00211081)
Timeframe: Baseline, Post-Intervention (4 Weeks)
| Intervention | pg/ml (Median) | |
|---|---|---|
| Baseline | 4 Week Follow Up | |
| Spironolactone | 1.96 | 1.54 |
The normal result for TNF-a is <5.6 pg/mL. (NCT00211081)
Timeframe: Baseline, Post-Intervention (4 Weeks)
| Intervention | pg/mL (Median) | |
|---|---|---|
| Baseline | 4 Week Follow Up | |
| Spironolactone | 2.20 | 2.42 |
2 other studies available for nitroglycerin and Homocystinuria
| Article | Year |
|---|---|
Vitamin C therapy ameliorates vascular endothelial dysfunction in treated patients with homocystinuria.
Topics: Adult; Ascorbic Acid; Blood Flow Velocity; Blood Pressure; Brachial Artery; Endothelium, Vascular; F | 2002 |
Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents.
Topics: Adolescent; Adult; Amino Acids; Brachial Artery; Child; Child, Preschool; Endothelium, Vascular; Fem | 1993 |